Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
- Sponsor
- Yonsei University
- Study ID
- NCT00832689
- Phase
- PHASE2
- Status
- Completed
Conditions
- Biliary Tract Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 17 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan and Gemcitabine — DRUG
Study Details
The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.
Key Dates
- Start date
- Jun 30, 2008
- Status verified
- Mar 2011
- Primary completion
- Feb 28, 2010
- Completion
- Mar 31, 2010
Study Design
- Enrollment
- 39 participants (actual)
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
Related Studies
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)PHASE2 · Recruiting · AstraZeneca · Los Angeles, California
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCPHASE2 · Recruiting · Replimune, Inc. · Beverly Hills, California
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerPHASE2 · Recruiting · AstraZeneca · Birmingham, Alabama